2. Search Result
Search Result
Results for "

kinase inhibitors

" in MedChemExpress (MCE) Product Catalog:

2823

Inhibitors & Agonists

13

Screening Libraries

7

Fluorescent Dye

8

Biochemical Assay Reagents

71

Peptides

1

MCE Kits

2

Inhibitory Antibodies

133

Natural
Products

90

Isotope-Labeled Compounds

23

Click Chemistry

7

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W844543
    Protein kinase inhibitor 12

    		Others Neurological Disease
    Protein Kinase Inhibitor 12 (compound 1-91) is a triazolopyridazine derivative and protein kinase inhibitor that can be utilized in research related to diseases associated with protein kinases .
    Protein kinase inhibitor 12
  • HY-161293
    p38-α MAPK-IN-6

    		p38 MAPK Cancer
    p38-α MAPK-IN-6 (compound 3a) is a p38α mitogen-activated protein kinase inhibitor .
    p38-α MAPK-IN-6
  • HY-144708
    Axl-IN-4

    		TAM Receptor Cancer
    Axl-IN-4 (Compound 24) is an AXL kinase inhibitor with an IC50 of 28.8 μM .
    Axl-IN-4
  • HY-169701
    Casein kinase 1δ-IN-22

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-22 (compound 484) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-22 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
    Casein kinase 1δ-IN-22
  • HY-169692
    Casein kinase 1δ-IN-21

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-21 (compound 501) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-21 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
    Casein kinase 1δ-IN-21
  • HY-169689
    Casein kinase 1δ-IN-19

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-19 (compound 492) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-19 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
    Casein kinase 1δ-IN-19
  • HY-169690
    Casein kinase 1δ-IN-20

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-20 (compound 427) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-20 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
    Casein kinase 1δ-IN-20
  • HY-169702
    Casein kinase 1δ-IN-23

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-23 (compound 423) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-22 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
    Casein kinase 1δ-IN-23
  • HY-169705
    Casein kinase 1δ-IN-24

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-24 (compound 489) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-24 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
    Casein kinase 1δ-IN-24
  • HY-169706
    Casein kinase 1δ-IN-25

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-25 (compound 487) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-25 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
    Casein kinase 1δ-IN-25
  • HY-169709
    Casein kinase 1δ-IN-26

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-26 (compound 505) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-26 can be used in the study of neurodegenerative diseases such as Alzheimer's disease .
    Casein kinase 1δ-IN-26
  • HY-149636
    Multi-target kinase inhibitor 2

    		EGFR CDK VEGFR Cancer
    Multi-target kinase inhibitor 2 (compound 5K) is a multi-targeted kinase inhibitor, and exhibits activity against EGFR, Her2, VEGFR2, and CDK2 enzymes, with IC50 values ranging from 40 to 204 nM. Multi-target kinase inhibitor 2 shows cytotoxic effects were observed against HepG2, HeLa , MDA-MB-231 and MCF-7, with IC50 of 41, 57, 51 and 59 μM. Multi-target kinase inhibitor 2 induces cell cycle arrest and apoptosis in HepG2 cells.
    Multi-target kinase inhibitor 2
  • HY-149694
    Aurora kinase inhibitor-12

    		Aurora Kinase Cancer
    Aurora kinase inhibitor-12 (Compound 1a ) is the inhibitor of aurora kinase which is a key enzyme that is implicated in tumor growth .
    Aurora kinase inhibitor-12
  • HY-163267
    ZNL0325

    		Fluorescent Dye Others
    ZNL0325 is a covalent probe based on pyrazolopyrimidine. ZNL0325 features an acrylamide side chain at the C3 position, which is capable of forming covalent bonds with multiple kinases that possess a cysteine at the αD-1 position, including BTK, EGFR, BLK, and JAK3. ZNL0325 can be used in the research of creating structurally distinct covalent kinase inhibitors .
    ZNL0325
  • HY-18817
    AFG210

    		Bcr-Abl FGFR Raf RET VEGFR Cancer
    AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC50=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase .
    AFG210
  • HY-169629
    CK2 inhibitor 4

    		Casein Kinase Cancer
    CK2 inhibitor 4 (compound 5b) is a protein kinase CK2 inhibitor with IC50 of 3.8 μM. CK2 inhibitor 4 can be used in tumor research .
    CK2 inhibitor 4
  • HY-133850
    10-DEBC

    		Pim Cancer
    10-DEBC is a selective Akt inhibitor. 10-DEBC shows strong inhibitory activity against Moloney murine leukemia virus (Pim) kinase-1 (IC50=1.28 μM) .
    10-DEBC
  • HY-137611A
    α,β-MTDP trisodium

    		DNA/RNA Synthesis Cancer
    α,β-MTDP trisodium, a thymidylate analog, is a thymidine kinase inhibitor with a Ki of 23 µM .
    α,β-MTDP trisodium
  • HY-160708
    Tie2 kinase inhibitor 3

    		Tie Cancer
    Tie2 kinase inhibitor 3 (compound 63) is a potent Tie-2 kinase inhibitor with good oral activity (IC50=30 nM). Tie2 kinase inhibitor 3 inhibits phosphorylation and signaling of Tie-2 by competing with the ATP binding site of Tie-2 kinase. This inhibition affects the stability and maturity of blood vessels, which has an impact on tumor angiogenesis. Tie2 kinase inhibitor 3 can be used to restrict tumor growth and regulate angiogenesis .
    Tie2 kinase inhibitor 3
  • HY-125957
    A-3 hydrochloride

    		PKA Casein Kinase CaMK PKC Others
    A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (Ki=4.3 μM), casein kinase II (Ki=5.1 μM) and myosin light chain kinase (MLCK) (Ki=7.4 μM). A-3 hydrochloride also inhibits PKC and casein kinase I with Ki values of 47 μM and 80 μM, respectively .
    A-3 hydrochloride
  • HY-164041
    Staurosporine-Boc

    		PKC Others
    Staurosporine-Boc, a natural product isolated from the actinomyces Streptomyces staurosporeus, is a potent non-selective inhibitor of protein kinase. Staurosporine-Boc inhibits a variety of protein kinases, including protein kinase C (PKC), tyrosine kinase, and serine/threonine kinase. Because of its broad inhibition profile, Staurosporine-Boc is widely used as a tool compound in biological research, especially when studying cell signaling pathways .
    Staurosporine-Boc
  • HY-138870
    Enzyme-IN-3 disodium

    		Bacterial Infection
    Enzyme-IN-3 disodium (compound 7) is a selective inhibitor of Mycobacterium tuberculosis shikimate kinase with an IC50 of 1.6 μM. Enzyme-IN-3 disodium has antibacterial activity .
    Enzyme-IN-3 disodium
  • HY-110039
    BIBX 1382 dihydrochloride

    		EGFR Infection
    BIBX 1382 dihydrochloride is an ErbB kinase inhibitor with significant antiviral activity. BIBX 1382 affects the ability of viruses to enter host cells by inhibiting members of the ErbB kinase family. It can be used to study the interaction mechanism between virus and host and the broad spectrum intervention of highly pathogenic viruses .
    BIBX 1382 dihydrochloride
  • HY-144706
    Axl-IN-3

    		TAM Receptor Cancer
    Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC50 of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases .
    Axl-IN-3
  • HY-17602
    Amcasertib

    BBI503

    		 Others Cancer
    Amcasertib (BBI503) is an orally active and small-molecule multi-kinase inhibitor. Amcasertib exhibits inhibitory activity against the NANOG and CD133 expression and cell viability in PC-9/GR cells. As an orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity, it is currently being studied in phase I clinical trials in a number of cancers.
    Amcasertib
  • HY-154956
    PIKfyve-IN-2

    		PIKfyve Inflammation/Immunology Cancer
    PIKfyve-IN-2 is a potent PIKfyve kinase inhibitor and can be used for cancers, autoimmune disorders research .
    PIKfyve-IN-2
  • HY-115840
    ICL-CCIC-0019

    		Apoptosis Cancer
    ICL-CCIC-0019 is an inhibitor of choline kinase α (CHKα). ICL-CCIC-0019 induces G1 block, endoplasmic reticulum stress apoptosis in cancer cell lines .
    ICL-CCIC-0019
  • HY-18764
    BpV(pic) potassium hydrate

    		PTEN Metabolic Disease
    BpV(pic) potassium hydrate is a PTEN inhibitor with IC50 31 nM. BpV(pic) potassium hydrate is also an insulin simulator that activates insulin receptor kinase in cultured liver cancer cells, stimulates adipogenesis in adipocytes, and inhibits the dephosphorylation of autophosphorylated insulin receptors and epidermal growth factor receptors in rat hepatosomes .
    BpV(pic) potassium hydrate
  • HY-N6794
    10Z-Hymenialdisine

    (Z)-Hymenialdisine; Hymenialdisine

    		 AMPK VEGFR PDGFR Cancer
    10Z-Hymenialdisine ((Z)-Hymenialdisine) is a natural bioactive pyrrole alkaloid. 10Z-Hymenialdisine is a pan kinase inhibitor, and has anticancer activities .
    10Z-Hymenialdisine
  • HY-163170
    FMF-04-159-R

    		CDK Cancer
    FMF-04-159-R is a cyclin-dependent kinase CDK14 and CDK16 inhibitor with IC50 values of 5.9 and 139.1 nM .
    FMF-04-159-R
  • HY-148810
    Zongertinib

    BI 1810631

    		 c-Met/HGFR Cancer
    Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors .
    Zongertinib
  • HY-156450
    ERK5-IN-5

    		ERK Cancer
    ERK5-IN-5 (compound 4a) is an ERK5 kinase inhibitor with anticancer activity. ERK5-IN-5 exhibits good anti-proliferative activity with the IC50 value of 6.23 µg/mL for A549 cells .
    ERK5-IN-5
  • HY-156451
    ERK5-IN-6

    		ERK Cancer
    ERK5-IN-6 (compound 5J) is an ERK5 kinase inhibitor with anticancer activity. ERK5-IN-6 exhibits good anti-proliferative activity with the IC50 value of 4.56 µg/mL for A549 cells .
    ERK5-IN-6
  • HY-10158
    Bosutinib
    15+ Cited Publications

    SKI-606

    		 Src Bcr-Abl Autophagy Cancer
    Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively .
    Bosutinib
  • HY-12570
    CK2-IN-9

    		Casein Kinase Wnt Cancer
    CK2-IN-9 is a potent and selective inhibitor of CK2 kinase with an IC50 of 3 nM. CK2-IN-9 reduces Wnt reporter activity with an IC50 of 75 nM. CK2-IN-9 has low exposure (AUC=0.36 μM/h) and high clearance (CL=65 mL/min/kg) properties in rat .
    CK2-IN-9
  • HY-110367
    LCB 03-0110 dihydrochloride

    		Src Others
    LCB 03-0110 dihydrochloride is a dihydrochloride of LCB 03-0110. LCB 03-0110 is a potent inhibitor of Src family tyrosine kinase .
    LCB 03-0110 dihydrochloride
  • HY-162489
    Tyrosine kinase-IN-8

    		Bcr-Abl Others
    Tyrosine kinase-IN-8 (compound 4e) is a BCR‐ABL1 tyrosine kinase inhibitor (TKI). Tyrosine kinase-IN-8 shows anti-proliferative activity against K562 cells, a chronic myeloid leukemia (CML) cell line (CC50=0.8 µM). Tyrosine kinase-IN-8 can be used in the study of chronic leukemia .
    Tyrosine kinase-IN-8
  • HY-148832
    BTK-IN-20

    		Btk Inflammation/Immunology Cancer
    BTK-IN-20 (compound 283) is a BTK tyrosine kinase inhibitor and a 1H-pyrazolo[3,4-d]pyrimidine derivative. BTK-IN-20 can be used for the research of cancer and inflammation .
    BTK-IN-20
  • HY-113787
    (R)-9b

    		Ack1 JAK Cancer
    (R)-9b is a potent inhibitor of ACK1 tyrosine kinase (IC50=56 nM) with anticancer activity. (R)-9b exhibits selectivity for ACK1 but has inhibitory effects on JAK family kinases JAK2 and Tyk2. (R)-9b can be used in the study of hormone-regulated cancers such as prostate and breast cancer .
    (R)-9b
  • HY-19562A
    PF-06260933 hydrochloride

    		MAP4K Inflammation/Immunology
    PF-06260933 hydrochloride is the hydrochloride form of PF-06260933 (HY-19562). PF-06260933 hydrochloride is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively .
    PF-06260933 hydrochloride
  • HY-101837
    CGP 53716

    		PDGFR Inflammation/Immunology
    CGP 53716 is a potent protein tyrosine kinase inhibitor. CGP 53716 has selective activity of platelet-derived growth factor (PDGF) receptor. CGP 53716 can be used in the study of disease induced by abnormal cell proliferation induced by PDGF receptor activation .
    CGP 53716
  • HY-150022
    GRK5-IN-4

    CCG-265328

    		 G Protein-coupled Receptor Kinase (GRK) Cardiovascular Disease
    GRK5-IN-4 (Compound 16d, CCG-265328) is a potent and and selective covalent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 1.1 μM. GRK5-IN-4 shows 90-fold selectivity over GRK2. GRK5-IN-4 can be used for heart failure research . GRK5-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    GRK5-IN-4
  • HY-167832
    PT109

    		JNK SGK ROCK Neurological Disease Inflammation/Immunology Cancer
    PT109 is a multi-kinase inhibitor. PT109 inhibits JNK (JNK1: IC50=0.143 μM; JNK2: IC50=0.831 μM; JNK3: IC50=0.285 μM) and other kinases (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM; ROCK2: IC50=34 μM) and plays an important role in anti-inflammation, anti-oxidation, neurogenesis, synaptogenesis, etc. In addition, PT109 also reprograms glioblastoma multiforme (GBM) into oligodendrocytes through the PTBP1/PKM1/2 pathway and changes the metabolic pattern of GBM, exerting anti-glioma activity .
    PT109
  • HY-142680
    EGFR-IN-23

    		EGFR Cancer
    EGFR-IN-23 is a potent EGFR TKI (tyrosine kinase inhibitor) with an IC50 of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8) .
    EGFR-IN-23
  • HY-149019
    Antitumor agent-70

    		c-Kit Apoptosis Cancer
    Antitumor agent-70 (compound 8b) has anti-tumor activity and can induce cell apoptosis. Antitumor agent-70 inhibits multiple myeloma with an IC50 value of 0.12 μM. Antitumor agent-70 is a potential multi-targeted kinase inhibitor especially for c-Kit .
    Antitumor agent-70
  • HY-124146
    BI1002494

    		Syk Inflammation/Immunology
    BI1002494 is an orally active, potent, and selective spleen tyrosine kinase (SYK) inhibitor. BI 1002494 exhibits an IC50 of 115 nM in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation. BI1002494 can be utilized in immunology reesearch .
    BI1002494
  • HY-153831
    c-Met-IN-17

    		c-Met/HGFR Cancer
    c-Met-IN-17 is a potent c-Met kinase inhibitor with an IC50 of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    c-Met-IN-17
  • HY-147243
    Ansornitinib

    ANG-3070

    		 VEGFR PDGFR Cardiovascular Disease Inflammation/Immunology
    Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .
    Ansornitinib
  • HY-146884
    MET kinase-IN-3

    		c-Met/HGFR VEGFR Cancer
    MET kinase-IN-3 (compound 8) is an orally active and potent MET inhibitor, with an IC50 of 9.8 nM. MET kinase-IN-3 shows good and broad-spectrum antiproliferative activity against cancer cell lines .
    MET kinase-IN-3
  • HY-171178
    DK2403

    		p38 MAPK Cancer
    DK2403 (compound 25) is a MAP2K7 inhibitor (IC50=0.01 μM). DK2403 can effectively inhibit MAP2K7 without significantly disrupting the larger kinase group and can be used to study childhood T-cell acute lymphoblastic leukemia .
    DK2403

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: